SeaStar Medical Announces $3.6M NIH Grant Award To Study Selective Cytopheretic Device In Adult Patients With Severe Chronic Heart Failure
Portfolio Pulse from Benzinga Newsdesk
SeaStar Medical has been awarded a $3.6 million grant from the National Institutes of Health (NIH) to study its Selective Cytopheretic Device (SCD) in adult patients with severe chronic heart failure. The study aims to explore the potential benefits of the SCD in treating this patient group.
April 30, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
SeaStar Medical's NIH grant to study the SCD in heart failure patients may indirectly benefit ICU Medical if the device shows positive outcomes and leads to increased demand.
While the article directly mentions SeaStar Medical's grant award, ICU Medical (ICU) is mentioned indirectly in relation to the healthcare sector. The potential success of the SCD in treating severe chronic heart failure could lead to increased demand for related medical devices and services, indirectly benefiting companies like ICU Medical. However, the direct impact on ICU Medical's stock price in the short term is uncertain, hence the neutral score.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50